

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

EPAS ID: PAT6685583

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
YIUMO CHAN	02/17/2021
ALEXANDRA TROTIER-FAURION	02/03/2021
WILLIAM F. BRUBAKER	04/24/2021
ARJUN NATESAN	02/01/2021
PAUL LEE	02/17/2021
SHARYL FYFFE-MARICICH	02/15/2021
DAVID LAPOINTE	02/01/2021
MIKE E. LIZARZABURU	02/18/2021
EMIL D. KAKKIS	02/10/2021
RECEIVING PARTY DATA	
Name:	ULTRAGENYX PHARMACEUTICAL INC.
Street Address:	60 LEVERONI COURT
City:	NOVATO
State/Country:	CALIFORNIA
Postal Code:	94949
PROPERTY NUMBERS Total: 1	
Property Type	Number
Application Number:	16764969
CORRESPONDENCE DATA	
Fax Number:	(202)842-7899
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	2028427800
Email:	harmstrong@cooley.com
Correspondent Name:	COOLEY LLP
Address Line 1:	1299 PENNSYLVANIA AVENUE, NW
Address Line 2:	ATTN: IP DOCKETING DEPARTMENT
Address Line 4:	WASHINGTON, D.C. 20004-2400
ATTORNEY DOCKET NUMBER:	ULPI-039/01US 315613-2480
NAME OF SUBMITTER:	ASAKO KUBOTA

PATENT

SIGNATURE:	/Asako Kubota/
DATE SIGNED:	04/30/2021
Total Attachments: 13 source=ULPI-039_01US_Assignment#page1.tif source=ULPI-039_01US_Assignment#page2.tif source=ULPI-039_01US_Assignment#page3.tif source=ULPI-039_01US_Assignment#page4.tif source=ULPI-039_01US_Assignment#page5.tif source=ULPI-039_01US_Assignment#page6.tif source=ULPI-039_01US_Assignment#page7.tif source=ULPI-039_01US_Assignment#page8.tif source=ULPI-039_01US_Assignment#page9.tif source=ULPI-039_01US_Assignment#page10.tif source=ULPI-039_01US_Assignment#page11.tif source=ULPI-039_01US_Assignment#page12.tif source=ULPI-039_01US_Assignment#page13.tif	

ASSIGNMENT

Yiumo CHAN, Emil D. KAKKIS, Alexandra TROTIER-FAURION, William F. BRUBAKER, Arjun NATESAN, Paul LEE, and Sharyl FYFFE-MARICICH, with a mailing address: c/o Ultragenyx Pharmaceutical Inc., 60 Leveroni Court, Novato, CA 94949; **David LAPOINTE**, residing at 676 42nd Street, Oakland, CA 94609, and **Mike E. LIZARZABURU**, residing at 1159 Palou Drive, Pacifica, CA 94044, (each referred to as "Assignor") have made an invention(s) (the "Invention(s)") set forth in an application for patent entitled **CREATINE PRODRUGS, COMPOSITIONS AND METHODS OF USE THEREOF**, and which is a:

- (1) ☐ provisional application
 - (a) ☐ to be filed herewith; or
 - (b) ☐ bearing Application No. , and filed on ;
- (2) ☒ non-provisional application
 - (a) ☐ to be filed herewith; or
 - (b) ☒ bearing Application No. **16/764,969**, and filed on **May 18, 2020**; and/or
- (3) ☒ PCT application
 - (a) ☒ bearing Application No. **PCT/US2018/063580**, and filed on **December 3, 2018**and/or
- (4) ☐ attached hereto.

WHEREAS, Ultragenyx Pharmaceutical Inc., a corporation having its principal place of business at 60 Leveroni Court, Novato, CA 94949, its successors, legal representatives and assigns, (the "Assignee"), is desirous of acquiring the entire right, title, and interest in: the Invention(s); the application(s) for patent identified above; the right to file applications for patent of the United States or other countries on the Invention(s); any application(s) for patent of the United States or other countries claiming priority to, and/or the benefit of, these applications; any provisional or other right to recover any and all past, present, and future damages, including royalties, for any and all past, present, and future infringements of these application(s); and any and all patent(s) of the United States or other countries that may be granted therefor or thereon.

NOW, THEREFORE, for good and sufficient consideration, the receipt of which is hereby acknowledged, and to the extent that the Assignor has not done so already via a prior

agreement with the Assignee or a predecessor in interest of the Assignee, or if the Assignor has already done so via a prior agreement with the Assignee or a predecessor in interest of the Assignee then in confirmation of said prior agreement, the Assignor has sold, assigned, transferred, and set over, and by these presents does sell, assign, transfer, and set over, unto the Assignee, its successors, legal representatives, and assigns, the Assignor's entire right, title, and interest in:

- (a) the Invention(s);
- (b) the application(s) for patent identified above;
- (c) the right to file applications for patent of the United States or other countries on the Invention(s), including all rights under the Hague Convention, the Paris Convention for the Protection of Industrial Property, and under the Patent Cooperation Treaty, and all rights of claiming priority in any country of the world;
- (d) any application(s) for patent of the United States or other countries claiming the Invention(s);
- (e) any application(s) for patent of the United States or other countries claiming priority to, and/or the benefit of, at least one of the application(s) for patent identified above or any application(s) for patent claiming the Invention(s), including any priority application(s), substitute application(s), division(s), continuation(s), and continuation(s)-in-part;
- (f) any provisional or other right to recover any and all past, present, and future damages, including royalties, for any and all past, present, and future infringements of any application for patent identified in the preceding paragraphs (b)-(e) and of any and all patent(s) granted based thereon in the United States and in all other countries; and
- (g) any patent(s) of the United States or other countries that may be granted for or on any application for patent identified in the preceding paragraphs (b)-(e), including any reissue(s), reexamination(s), revival(s), renewal(s) and extension(s) of said patent(s).

The above-granted rights, titles, and interests are to be held and enjoyed by the Assignee, for its own use and behalf and the use and behalf of its successors, legal representatives, and assigns, as fully and entirely as the same would have been held and enjoyed by the Assignor had this sale and assignment not been made.


The Assignor hereby represents to the Assignee, its successors, legal representatives, and assigns, that, at the time of execution and delivery of these presents, or if applicable, at such time said prior agreement was executed, the Assignor is a lawful owner of an undivided interest in the entire right, title, and interest in and to the Invention(s), that the Invention(s) are unencumbered, except, if applicable, by obligation to assign in accordance with said prior agreement, and that the Assignor has good and full right and lawful authority to sell and convey the same in the manner set forth herein, and that Assignor will not make or enter into any assignment, sale, agreement or encumbrance which would conflict with these presents.

The Assignor hereby covenants and agrees to and with the Assignee, its successors, legal representatives, and assigns, that the Assignor will sign all papers and documents, take all lawful oaths, and do all acts necessary or required to be done in connection with any and all proceedings for the procurement, maintenance, enforcement and defense of the Invention(s), said application(s), and said patent(s), including interference and derivation proceedings, and any post-grant proceedings (e.g., opposition proceedings, post-grant reviews, *Inter partes* reviews, supplemental examinations, etc.) without charge to the Assignee, its successors, legal representatives, and assigns, but at the cost and expense of the Assignee, its successors, legal representatives, and assigns.

The Assignor hereby authorizes and requests the attorneys of COOLEY LLP to insert in the spaces provided above the filing date, the application number, and the attorney docket number of the application(s) identified above when known.

The Assignor hereby requests the Commissioner of Patents to issue said patents of the United States to the Assignee for the sole use and behalf of the Assignee, its successors, legal representatives, and assigns.

Date: 17-Feb-2021

Inventor: 
Yiumo CHAN

Date: 17-Feb-2021

Witnessed By: 
Jennifer CHAN < spouse >

Date:

Feb 10, 2021

Inventor:



Emil D. KAKKIS

Date:

Witnessed By:

Date: February 3rd, 2021

Inventor: 
Alexandra TROTIER-FAURION

Date: February 3rd, 2021

Witnessed By: 
Laurent BENKETOUN

Date: April 24 2021

Inventor: William F Brubaker
William F. BRUBAKER

Date: April 24, 2021

Witnessed By: Mary Beth Brubaker

Date: Feb. 1, 2021

Inventor: Arjun Natesan
Arjun NATESAN

Date: Feb. 1, 2021

Witnessed By: Ellen Natesan
Ellen Natesan

Date: 17 FEB 2021

Inventor: 
Paul LEE

Date: 17 FEB 2021

Witnessed By: 
DANIEL ALCANTARA-LEE


Date: 2/15/21

Inventor: Sharyl Fyffe-M
Sharyl FYFFE-MARICICH


Date: 2/15/21

Witnessed By: [Signature]


Date: 2/1/2021

Inventor: 
David LAPOINTE


Date: 2/1/2021

Witnessed By: 

Date: 02/18/2021

Inventor: 
Mike E. LIZARZABURU

Date: 2/25/2021

Witnessed By: 

For and on behalf of ASSIGNEE:

Date: April 29 2021

By: Paul Wickman
Name: Paul Wickman
Title: SVP, Intellectual Property
Company: Ultragenyx Pharmaceutical Inc.

Date: 4/29/2021

Witnessed By: Brenda Pankowski-Wickman
Brenda Pankowski-Wickman

224379114 v1